FDA Approves Investigational Device Exemption for Agili-C Implant

CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.

The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

  • This field is for validation purposes and should be left unchanged.

0